AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors. Thus, it is sold online as a designer drug. It was originally developed by Pfizer which described the compound in a patent in 2009.
Pharmacology of FUB-AMB(AMB-FUBINACA)
The most likely route of administration for AMB-FUBINACA is inhalation via smoking. Here, the chemical is sprayed on plant material then vaped after
formulation in liquid.
Dosage required for pharmacological effects in humans is unknown. Little is known about its absorption, distribution, elimination or time course. Investigation of the pharmacokinetics of AMB-FUBINACA has focused on delineation of its metabolism.
There is emphasis on identifying unique metabolites that may be used for forensic purposes. Ten metabolites of FUB-AMB have been identified in human hepatocytes, with verification of the major metabolites in authentic human urine.. It undergoes extensive biotransformation that is focused on hydroxylation of its cyclohexylmethyl tail.